To evaluate consistency of efficacy and safety results for high-dose spironolactone with alternate eGFR cutpoints, sensitivity analyses using clinical eGFR definitions aligned with the stages of chronic kidney disease were performed (i
The mineralocorticoid antagonist spironolactone is efficacious in patients with heart failure
swelling of the face, fingers, feet, ankles, or lower legs
Monitor renal function and sodium and potassium within a month of commencing treatment and repeat as needed
Aim: Mineralocorticoid receptor blockade (MRBs) in combination with angiotensin converting enzyme (ACE) inhibitors and angiotensin-II receptor blockade (ARBs) improve prognostic markers of cardiovascular and renal disease in early stage chronic kidney disease (CKD)
Drug interactions, dosage, and pregnancy and breastfeeding information are provided
Spironolactone has been linked to rare cases of clinically apparent drug induced liver disease
January 8, 2019